Rounds / The Phage
TPThe Phage raises ¥570M (Series A)
Develops CGFM, a foundation model trained on continuous blood-glucose data to predict post-meal glucose swings; capital and business alliance with Tokio Marine.
- Company
- The Phage
- Reported
- 9 Oct 2026 · that week's brief
- Stage
- Series A · 「シリーズA」 · A
- Amount
- ¥570M1 · as announced: 「総額5.7億円」
- Breakdown
- Equity not disclosed separately
- Status
- In scopeNot yet registry-confirmed
- Notes
- Third-party allotment plus Shoko Chukin loan; split not disclosed
- Investors
- Not listed in our summary; see source
- Sector
- Healthcare
- Source
- Primary release (PR TIMES) · BRIDGE coverage
1 ≈ ~$3.6M at the ECB reference rate on 2026-10-09 (¥1 = $0.00632). Yen is the figure of record. Methodology
Get the weekly brief
Every Japanese funding round worth knowing, in one English email. Free. Subscribe on Substack →
Every Japanese funding round worth knowing, in one English email. Free. Subscribe on Substack →